By Amechi Idumuebor, For Agenda Watchdog, May 18, 2020
(AGENDAWATCHDOG) – Moderna’s experimental COVID-19 vaccine produced antibodies that could ‘neutralize’ the new coronavirus in patients in a small early stage clinical trial, the company announced Monday, sending its shares up by more than 20 percent.
The levels of the antibodies – immune cells made in response to a germ, which may provide protection against reinfection – were similar to those in blood samples of people who have recovered from COVID-19, early results from the study conducted by the National Institutes of Health (NIH) showed.
Participants were given three different doses of the vaccine and Moderna said it saw dose-dependent increase in immunogenicity, the ability to provoke an immune response in the body.
Moderna noted that the early trial is intended to determine the safety and side effects of the vaccine and, although the early results are promising, it’s too soon to say whether the shot candidate can actually block the virus.